Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | COMT | P21964 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9442593 | 0.80 | KDM4E (0.45) | KDM4EKMT2AMEN1POLBCOMT | |
| SCHEMBL2959778 | 0.79 | KDM4E (0.55) | KDM4EKMT2AMEN1POLBMAPT | |
| SCHEMBL31413120 | 0.79 | HPGD (0.44) | KDM4EKMT2AMEN1POLBMAPT | |
| SCHEMBL1760863 | 0.78 | MAPT (0.43) | KDM4EKMT2APOLBMAPTTSHR | |
| SCHEMBL3581664 | 0.78 | MAPT (0.50) | KDM4EKMT2APOLBMAPTTSHR | |
| SCHEMBL25468236 | 0.78 | CYP1A2 (0.43) | KDM4EKMT2AMEN1POLBMAPT | |
| SCHEMBL13592553 | 0.77 | KDM4E (0.41) | KDM4EKMT2AMEN1POLBMAPT | |
| SCHEMBL13227172 | 0.76 | KMT2A (0.44) | KDM4EKMT2AMEN1POLBMAPT | |
| SCHEMBL31078546 | 0.75 | DPP4 (0.45) | KDM4EKMT2AMEN1POLBMAPT | |
| SCHEMBL2953619 | 0.75 | KMT2A (0.48) | KDM4EKMT2AMEN1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-08-01 | — | — | US | disclosed |
| EP-3625222-B1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-07-21 | — | — | EP | disclosed |
| US-20200179383-A1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2020-06-11 | — | — | US | disclosed |
| EP-3625222-A1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2020-03-25 | — | — | EP | disclosed |
| CN-110612296-A | Phenyl derivatives as PGE2 receptor modulators | 爱杜西亚药品有限公司 | 2019-12-24 | — | — | CN | disclosed |
| WO-2018210994-A1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-11-22 | — | — | WO | disclosed |
| CN-1025027-C | Organic compounds and their use as pharmaceuticals | LILLY SA (ES) | 1994-06-15 | — | — | CN | disclosed |
| EP-0297697-B1 | Thiophene-2-carboxamide derivatives and their pharmaceutical use | LILLY SA (ES) | 1993-12-29 | — | — | EP | disclosed |
| US-4904686-A | 3-ALKOXYTHIOPHENE-2-CARBOXAMIDES; CENTRAL NERVOUS SYSTEM DISORDERS | LILLY INDUSTRIES LIMITED (GB) | 1990-02-27 | — | — | US | disclosed |
| CN-1030916-A | Organic compound and as the application of medicine | LILLY SA (ES) | 1989-02-08 | — | — | CN | disclosed |
| EP-0297697-A1 | Thiophene-2-carboxamide derivatives and their pharmaceutical use | LILLY S.A. (ES) | 1989-01-04 | — | — | EP | disclosed |
| US-4119727-A | HYPOTENSIVE AGENTS | ROUSSEL UCLAF (FR) | 1978-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11712438-B2 | Phenyl derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | KDM4E 842/4885KMT2A 1790/4885MEN1 4151/4885 |
| US-20200179383-A1 | PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | KDM4E 791/4885KMT2A 1625/4885MEN1 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.